| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Cancer Research, Vol 1, Issue 11 1253-1258, Copyright © 1995 by American Association for Cancer Research
ARTICLES |
W Debinski, NI Obiri, SK Powers, I Pastan and RK Puri
The Milton S. Hershey Medical Center, The Pennsylvania State University College of Medicine, Department of Surgery, Division of Neurosurgery, Hershey, Pennsylvania 17033, USA. debinski@debin.nsr.hmc.psu.edu
Recently, we have demonstrated that a spectrum of human adenocarcinoma cell lines express binding sites for interleukin 13 (IL-13). These cells are killed by a chimeric protein composed of human (h) IL-13 and a derivative of Pseudomonas exotoxin, PE38QQR (Debinski et al., J. Biol. Chem., 270: 16775-16780, 1995). The cell killing was hIL-13- and hIL-4-specific, indicating that a common binding site for the two cytokines is present in several solid tumor cell lines. Herein, we report that an array of established glioma cell lines is killed by very low concentrations of hIL-13-PE38QQR, often reaching <1 ng/ml (<20 pM). Glioma cells express up to 30,000 molecules of IL-13 receptor/cell which has intermediate affinity toward hIL-13. hIL-13-PE38QQR is more active (up to 3 logs difference in cytotoxic activities) than are the corresponding chimeric toxins containing hIL-4 or hIL-6. The cytotoxic action of hIL-13-PE38QQR is blocked by an excess of hIL-13 on all cell lines studied, and it is not neutralized by hIL-4 on some of these cells. Our results show that human brain cancers richly express receptors for IL-13. Furthermore, the interaction detected previously between receptors for IL-13 and IL-4 on solid tumors cell lines is of a qualitatively different character in U-251 MG and U-373 MG glioma cells. The receptor for IL-13 may represent a new marker of brain cancers and an attractive target for anticancer therapies.
This article has been cited by other articles:
|
|
 |
|
  D A Vallera, B J Stish, Y Shu, H Chen, A Saluja, D J Buchsbaum, and S M Vickers Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model Gut, May 1, 2008; 57(5): 634 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. H. Joshi, R. A. Puri, P. Leland, F. Varricchio, G. Gupta, M. Kocak, R. J. Gilbertson, R. K. Puri, and the U.S. Pediatric Brain Tumor Consortium Identification of interleukin-13 receptor {alpha}2 chain overexpression in situ in high-grade diffusely infiltrative pediatric brainstem glioma Neuro-oncol, January 1, 2008; 10(3): 265 - 274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wykosky, D. M. Gibo, C. Stanton, and W. Debinski Interleukin-13 Receptor {alpha}2, EphA2, and Fos-Related Antigen 1 as Molecular Denominators of High-Grade Astrocytomas and Specific Targets for Combinatorial Therapy Clin. Cancer Res., January 1, 2008; 14(1): 199 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Schwartzbaum, A. Ahlbom, S. Lonn, B. Malmer, A. Wigertz, A. Auvinen, A. J. Brookes, H. Collatz Christensen, R. Henriksson, C. Johansen, et al. An International Case-Control Study of Interleukin-4R{alpha}, Interleukin-13, and Cyclooxygenase-2 Polymorphisms and Glioblastoma Risk Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2448 - 2454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Jarboe, K. R. Johnson, Y. Choi, R. R. Lonser, and J. K. Park Expression of Interleukin-13 Receptor {alpha}2 in Glioblastoma Multiforme: Implications for Targeted Therapies Cancer Res., September 1, 2007; 67(17): 7983 - 7986. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kunwar, M. D. Prados, S. M. Chang, M. S. Berger, F. F. Lang, J. M. Piepmeier, J. H. Sampson, Z. Ram, P. H. Gutin, R. D. Gibbons, et al. Direct Intracerebral Delivery of Cintredekin Besudotox (IL13-PE38QQR) in Recurrent Malignant Glioma: A Report by the Cintredekin Besudotox Intraparenchymal Study Group J. Clin. Oncol., March 1, 2007; 25(7): 837 - 844. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kioi, S. Seetharam, and R. K. Puri N-linked glycosylation of IL-13R{alpha}2 is essential for optimal IL-13 inhibitory activity FASEB J, November 1, 2006; 20(13): 2378 - 2380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J.A. Murad, S. Walbridge, P. F. Morrison, K. Garmestani, J. W. Degen, M. W. Brechbiel, E. H. Oldfield, and R. R. Lonser Real-time, Image-Guided, Convection-Enhanced Delivery of Interleukin 13 Bound to Pseudomonas Exotoxin. Clin. Cancer Res., May 15, 2006; 12(10): 3145 - 3151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. Hockaday, S. Shen, J. Fiveash, A. Raubitschek, D. Colcher, A. Liu, V. Alvarez, and A. N. Mamelak Imaging Glioma Extent with 131I-TM-601 J. Nucl. Med., April 1, 2005; 46(4): 580 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S. Kahlon, C. Brown, L. J. N. Cooper, A. Raubitschek, S. J. Forman, and M. C. Jensen Specific Recognition and Killing of Glioblastoma Multiforme by Interleukin 13-Zetakine Redirected Cytolytic T Cells Cancer Res., December 15, 2004; 64(24): 9160 - 9166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kawakami, M. Kawakami, and R. K. Puri Nitric Oxide Accelerates Interleukin-13 Cytotoxin-Mediated Regression in Head and Neck Cancer Animal Model Clin. Cancer Res., August 1, 2004; 10(15): 5264 - 5270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Todhunter, W. A. Hall, E. Rustamzadeh, Y. Shu, S. O. Doumbia, and D. A. Vallera A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model Protein Eng. Des. Sel., February 1, 2004; 17(2): 157 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-h. Wu and W. C. Low Molecular cloning and identification of the human interleukin 13 alpha 2 receptor (IL-13Ra2) promoter Neuro-oncol, July 1, 2003; 5(3): 179 - 187. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Jakubzick, E. S. Choi, S. L. Kunkel, B. H. Joshi, R. K. Puri, and C. M. Hogaboam Impact of Interleukin-13 Responsiveness on the Synthetic and Proliferative Properties of Th1- and Th2-Type Pulmonary Granuloma Fibroblasts Am. J. Pathol., May 1, 2003; 162(5): 1475 - 1486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Madhankumar, A. Mintz, and W. Debinski Alanine-scanning Mutagenesis of alpha -Helix D Segment of Interleukin-13 Reveals New Functionally Important Residues of the Cytokine J. Biol. Chem., November 1, 2002; 277(45): 43194 - 43205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Jakubzick, S. L. Kunkel, B. H. Joshi, R. K. Puri, and C. M. Hogaboam Interleukin-13 Fusion Cytotoxin Arrests Schistosoma mansoni Egg-Induced Pulmonary Granuloma Formation in Mice Am. J. Pathol., October 1, 2002; 161(4): 1283 - 1297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. H. Joshi, K. Kawakami, P. Leland, and R. K. Puri Heterogeneity in Interleukin-13 Receptor Expression and Subunit Structure in Squamous Cell Carcinoma of Head and Neck: Differential Sensitivity to Chimeric Fusion Proteins Comprised of Interleukin-13 and a Mutated Form of Pseudomonas Exotoxin Clin. Cancer Res., June 1, 2002; 8(6): 1948 - 1956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Li, W. A. Hall, N. Jin, D. A. Todhunter, A. Panoskaltsis-Mortari, and D. A. Vallera Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice Protein Eng. Des. Sel., May 1, 2002; 15(5): 419 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Vallera, C. Li, N. Jin, A. Panoskaltsis-Mortari, and W. A. Hall Targeting Urokinase-Type Plasminogen Activator Receptor on Human Glioblastoma Tumors With Diphtheria Toxin Fusion Protein DTAT J Natl Cancer Inst, April 17, 2002; 94(8): 597 - 606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Debinski, B. H. Joshi, G. E. Plautz, and R. K. Puri Correspondence re: B. H. Joshi et al., Interleukin-13 Receptor {alpha} Chain: A Novel Tumor-associated Transmembrane Protein in Primary Explants of Human Malignant Gliomas. Cancer Res., 60: 1168-1172, 2000. Cancer Res., July 1, 2001; 61(14): 5660 - 5660. [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Husain and R. K. Puri Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi's sarcoma xenograft Blood, June 1, 2000; 95(11): 3506 - 3513. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Oshima, B. H. Joshi, and R. K. Puri Conversion of Interleukin-13 into a High Affinity Agonist by a Single Amino Acid Substitution J. Biol. Chem., May 5, 2000; 275(19): 14375 - 14380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. H. Joshi, G. E. Plautz, and R. K. Puri Interleukin-13 Receptor {{alpha}} Chain: A Novel Tumor-associated Transmembrane Protein in Primary Explants of Human Malignant Gliomas Cancer Res., March 1, 2000; 60(5): 1168 - 1172. [Abstract] [Full Text]
|
|
|
|
|
|
J. P. Thompson and W. Debinski Mutants of Interleukin 13 with Altered Reactivity toward Interleukin 13 Receptors J. Biol. Chem., October 15, 1999; 274(42): 29944 - 29950. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Debinski, D. M. Gibo, S. W. Hulet, J. R. Connor, and G. Y. Gillespie Receptor for Interleukin 13 Is a Marker and Therapeutic Target for Human High-Grade Gliomas Clin. Cancer Res., May 1, 1999; 5(5): 985 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Manna and B. B. Aggarwal IL-13 Suppresses TNF-Induced Activation of Nuclear Factor-{kappa}B, Activation Protein-1, and Apoptosis J. Immunol., September 15, 1998; 161(6): 2863 - 2872. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Debinski, R. Miner, P. Leland, N. I. Obiri, and R. K. Puri Receptor for Interleukin (IL) 13Does Not Interact with IL4 but Receptor for IL4 Interacts with IL13 on Human Glioma Cells J. Biol. Chem., September 13, 1996; 271(37): 22428 - 22433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Oshima and R. K. Puri Characterization of a Powerful High Affinity Antagonist That Inhibits Biological Activities of Human Interleukin-13 J. Biol. Chem., April 27, 2001; 276(18): 15185 - 15191. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
